NCT03692130

Brief Summary

Randomized trial to proof the effects and efficacy of a new mindfulness and acceptance based group-treatment for depressive patients

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 23, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

October 2, 2018

Completed
6 months until next milestone

Study Start

First participant enrolled

March 18, 2019

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
Last Updated

August 20, 2021

Status Verified

August 1, 2021

Enrollment Period

2.7 years

First QC Date

August 23, 2018

Last Update Submit

August 19, 2021

Conditions

Keywords

AcceptanceMindfulnessCommitmentGroup-Psychotherapy

Outcome Measures

Primary Outcomes (1)

  • Depression - Patient Health Questionnaire-9

    Measurement of changes of depressive Symptoms, so called PHQ-9. There will be a measure of the total score, range from 9 to 36, pathological in sense of depression will be any score above 15. There is only one measurement scale (PHQ-9) with nine items, no other measurements or different units in the PHQ-9.

    Measurement of PHQ-Data 3 months after inclusion of participant

Secondary Outcomes (3)

  • Quality of Life - European Quality 5 Dimensions on 3 Levels

    Measurement of QoL 3 months after inclusion of participant

  • Anxiety - Generalized Anxiety Disorder

    Measurement of Generalized Anxiety 3 months after inclusion of participant

  • Acceptance and Commitment - Questionnaire of Mindfulness, Acceptance and Commitment (MAC-Q)

    Measurement of Mindfulness, Acceptance and Commitment 3 months after inclusion of participant

Study Arms (2)

New Treatment

ACTIVE COMPARATOR

The patients will be treated with psychological group treatment for 8 Sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process.This will be called "Mindfulness, Acceptance and Commitment-Therapy for depressive Patients".

Behavioral: Mindfulness, Acceptance and Commitment-Therapy

Known Treatment

SHAM COMPARATOR

The participants will be treated with a relaxation-treatment, long time established as "jacobson muscle relaxing technique".

Behavioral: Jacobson

Interventions

Psychotherapeutic intervention to treat depressive patients with special exercises and education to be mindful, to accept situations and behaviors and to commit with the situation or the possibility to change.

New Treatment
JacobsonBEHAVIORAL

Relaxation treatment in technique of Jacobson

Known Treatment

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Depressive Disorder

You may not qualify if:

  • Somatic disorder
  • psychotic disorder
  • personality disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Neuropsychiatric Center of Hamburg

Hamburg, 22769, Germany

Location

MeSH Terms

Conditions

Depression

Interventions

Mindfulness

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Intervention Hierarchy (Ancestors)

Cognitive Behavioral TherapyBehavior TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Peter Tonn, MD

    Managing Director

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
The participants don't know in which of the both arms they are, the outcome assessor don't know which participant of which study-arm he/she calculate
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: One group with new treatment, one group with known and defined treatment
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

August 23, 2018

First Posted

October 2, 2018

Study Start

March 18, 2019

Primary Completion

December 1, 2021

Study Completion

March 1, 2022

Last Updated

August 20, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will not share

Locations